AstraZeneca at American College of Cardiology’s 68th Annual Scientific Session 2019

Clinical research advances in cardiovascular and metabolic diseases

We are proud to present our latest clinical research advances and real-world data in cardiovascular and metabolic diseases at the American College of Cardiology’s (ACC) 68th Annual Scientific Session in New Orleans, Louisiana, USA, on 16-18 March 2019.

At ACC 2019, we will share how our extensive clinical programmes are helping deliver an important body of evidence to better understand the interconnectivity of cardiovascular and metabolic diseases, as well as how to optimise the management of these diseases and their associated risk factors. This is particularly important when it comes to tackling the prevalence and burden of heart failure, which is a disease that effects 64 million people globally1 and is the most frequent cardiovascular complication in patients with type-2 diabetes.2

By sharing these important clinical insights with the cardiology community, we hope to demonstrate the need to take early action in these chronic diseases that impact millions of peoples’ lives.

Follow us on Twitter and LinkedIn, and join the conversation using #ACC19.


AstraZeneca at #ACC19


1 GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211-1259.

2 Kasznicki, J., & Drzewoski, J. (2014). Heart failure in the diabetic population - pathophysiology, diagnosis and management. Archives of medical science: AMS, 10(3), 546-56.


Veeva ID: Z4-15600

Date of expiry: March 2021